Get the Stockscreener App
242.97
0.50%
0.71
Alnylam Pharmaceuticals Inc stock is traded at $242.97, with a volume of 185.90K.
It is up +0.50% in the last 24 hours and down -0.58% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$242.26
Open:
$241.7
24h Volume:
185.90K
Relative Volume:
0.25
Market Cap:
$30.94B
Revenue:
$2.09B
Net Income/Loss:
$-332.26M
P/E Ratio:
-58.69
EPS:
-4.14
Net Cash Flow:
$16.06M
1W Performance:
-1.27%
1M Performance:
-0.58%
6M Performance:
+9.22%
1Y Performance:
+27.45%
1-Day Range:
$236.70
$243.90
1-Week Range:
$233.41
$247.21
52-Week Range:
$141.97
$304.39
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
243.07 | 30.94B | 2.09B | -332.26M | 16.06M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.09 | 105.01B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
711.77 | 78.17B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
630.47 | 37.48B | 1.86B | -40.29M | -1.28B | -0.85 |
|
BNTX
Biontech Se Adr
|
113.97 | 27.15B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Performing Biotech Stock in 2024? - Insider Monkey
When (ALNY) Moves Investors should Listen - Stock Traders Daily
Sanctuary Advisors LLC Boosts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
City: Taking RNAi beyond the liver - BioCentury
The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam - Yahoo Finance
4 Biotech Stocks Most Wall Street Analysts Are Bullish About - Yahoo Finance
Biotech CEO on RNAI and Medicine of the Future - Barron's
RNAi Technology Market to Witness Huge Growth by 2031 | Alnylam - openPR
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded by StockNews.com to "Buy" Rating - MarketBeat
Alnylam Pharmaceuticals' SWOT analysis: strong data bolsters amvuttra stock outlook - Investing.com
Gene Therapy Market Key Players AnalysisNovartis Ag, Biogen - openPR
What Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) P/S Is Not Telling You - Simply Wall St
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Update - MarketBeat
Toronto Dominion Bank Acquires 3,315 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam's SWOT analysis: strong helios-b data bolsters amvuttra stock outlook - Investing.com India
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Boosted by Tidal Investments LLC - MarketBeat
Insider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Sells 1,752 Shares of Stock - MarketBeat
Geode Capital Management LLC Acquires 66,928 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Kovitz Investment Group Partners LLC Acquires New Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam's Onpattro Drug Uses Patented UTexas Tech, Suit Says (1) - Bloomberg Law
Where are the Opportunities in (ALNY) - Stock Traders Daily
Public Employees Retirement System of Ohio Sells 3,275 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Bleeding Disorders Treatment Market Emerging Trends and Growth - openPR
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Nomura Asset Management Co. Ltd. - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
CAMP4 Therapeutics Taps Former Alnylam CEO, RNA Pioneer to Drive Next-Gen Gene Therapy Platform - StockTitan
Groupama Asset Managment Sells 2,849 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today - Benzinga
FAP therapy nucresiran safely reduces TTR in healthy people: Trial - FAP News Today
RNAi Therapeutics and Technology Market Top Players -Alnylam, - openPR
Two Sigma Advisers LP Sells 155,600 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
AL Amyloidosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Janssen Pharma, Prothena, Alexion Pharma, Alnylam Pharma, Attralus, Neurimmune AG - The Globe and Mail
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Polar Asset Management Partners Inc. - MarketBeat
Janus Henderson Group PLC Has $60.32 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Position Decreased by HighTower Advisors LLC - MarketBeat
Oligonucleotide Therapy Market Key Players AnalysisBPCI - openPR
Dyslipidemia Pipeline 2024: Clinical Trials Assessment, FDA - openPR
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Investment Management Corp of Ontario - MarketBeat
Royal London Asset Management Ltd. Has $76.94 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Small Interfering RNA (siRNA) Therapeutics Market Key Players - openPR
What Makes Alnylam (ALNY) a New Buy Stock - Yahoo Finance
Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Parkman Healthcare Partners LLC Invests $7.01 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp - MarketBeat
16,510 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Purchased by Erste Asset Management GmbH - MarketBeat
Bridgewater Associates LP Acquires New Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Why Is Alnylam Pharmaceuticals, Inc. (ALNY) Among the Best High Growth Healthcare Stocks to Invest In Now? - Yahoo Finance
PDT Partners LLC Decreases Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Bellevue Group AG Sells 110,739 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
10 High Growth Healthcare Stocks to Invest in Now - Insider Monkey
Eventide Asset Management LLC Buys 137,333 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):